168 related articles for article (PubMed ID: 32994808)
1. Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
Tagliaferri B; Quaquarini E; Palumbo R; Balletti E; Presti D; Malovini A; Agozzino M; Teragni CM; Terzoni A; Bernardo A; Villani L; Sottotetti F
Ther Adv Med Oncol; 2020; 12():1758835920958355. PubMed ID: 32994808
[TBL] [Abstract][Full Text] [Related]
2. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
3. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
5. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
6. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
Bronte G; Rocca A; Ravaioli S; Scarpi E; Bonafè M; Puccetti M; Maltoni R; Andreis D; Martinelli G; Bravaccini S
J Oncol; 2019; 2019():1393505. PubMed ID: 31110518
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
9. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
11. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
12. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes.
Orrù S; Pascariello E; Sotgiu G; Piras D; Saderi L; Muroni MR; Carru C; Arru C; Mocci C; Pinna G; Barbara R; Cossu-Rocca P; De Miglio MR
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052843
[TBL] [Abstract][Full Text] [Related]
14. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer.
Kang YJ; Lee HB; Kim YG; Han J; Kim Y; Yoo TK; Lee ES; Moon HG; Noh DY; Han W
J Oncol; 2019; 2019():7386734. PubMed ID: 31975992
[TBL] [Abstract][Full Text] [Related]
16. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression inversely correlates with histological grade and N stage in ER
Scatena C; Scarpitta R; Innocenti L; Miccoli M; Biancotti R; Diodati L; Ghilli M; Naccarato AG
Breast Cancer Res Treat; 2020 Jul; 182(1):55-65. PubMed ID: 32436149
[TBL] [Abstract][Full Text] [Related]
18. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
[TBL] [Abstract][Full Text] [Related]
19. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
